Industry to pay for UK agency fees hike as full regulatory costs recovery begins
This article was originally published in Clinica
Executive Summary
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) must now, for the first time, achieve full cost recovery for medical device regulatory activities, in line with what has been the case for some considerable time in the pharmaceutical sector. And medical device manufacturers will be meeting those costs.